Haleon Recalls Two Versions of Robitussin Due to Microbial Contamination
By Denny Jacob
Haleon voluntarily recalled two versions of cough medicine Robitussin due to a microbial contamination.
The personal healthcare products provider said the recall affects eight lots of Robitussin Honey CF Max Day Adult and Robitussin Honey CF Max Nighttime Adult at the consumer level.
Haleon said the use of the affected product in immunocompromised individuals could potentially result in severe or life-threatening adverse events such as fungemia or disseminated fungal infection. In non-immunocompromised consumers, the population most likely to use the product, life-threatening infections aren't likely to occur, it added.
Haleon said to date it hasn't received reports of adverse events related to the recall.
Write to Denny Jacob at denny.jacob@wsj.com
(END) Dow Jones Newswires
January 24, 2024 10:43 ET (15:43 GMT)
Copyright (c) 2024 Dow Jones & Company, Inc.-
5 Things We Learned From the Q1 Earnings Season
-
After Earnings, Is Palantir Stock a Buy, a Sell, or Fairly Valued?
-
What’s Happening In the Markets This Week
-
Can the Fed Declare Victory on Inflation?
-
After Earnings, Is Coinbase Stock a Buy, a Sell, or Fairly Valued?
-
After Earnings, Is Albemarle Stock a Buy, a Sell, or Fairly Valued?
-
Is ServiceNow Stock a Buy After Earnings and Its Investor Day?
-
3 Stocks to Buy and 3 Stocks to Sell After Earnings
-
Today’s Market Volatility Could Provide Tomorrow’s Opportunities
-
40 of the Best Investment Picks
-
Tech Stock Dividends Are Changing the Face of Dividend Growth Investing
-
Roblox Earnings: Weakening Engagement Has Weighed On Growth
-
The Best Gaming Stocks to Buy
-
Energy Transfer Earnings: M&A Drives Guidance Increase In Solid Quarter
-
The Best Healthcare Stocks to Buy
-
Going Into Earnings, Is Home Depot Stock a Buy, a Sell, or Fairly Valued?